Susquehanna International Group, LLP Scynexis Inc Call Options Transaction History

Susquehanna International Group, LLP

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$1.27 - $2.23 $8,255 - $14,495	-6,500 Reduced 35.91%	11,600 $17,000
Q2 2024 Aug 15, 2024	BUY	$1.4 - $2.77 $25,340 - $50,137	18,100 New	18,100 $36,000
Q3 2023 Nov 14, 2023	BUY	$1.93 - $3.64 $68,708 - $129,584	35,600 New	35,600 $81,000
Q1 2023 May 16, 2023	BUY	$1.15 - $3.0 $2,645 - $6,900	2,300 Added 3.45%	68,900 $206,000
Q4 2022 Feb 14, 2023	BUY	$1.46 - $2.94 $97,236 - $195,804	66,600 New	66,600 $103,000
Q2 2022 Aug 15, 2022	SELL	$1.77 - $3.87 $195,054 - $426,474	-110,200 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$3.56 - $6.66 $173,016 - $323,676	48,600 Added 78.9%	110,200 $431,000
Q4 2021 Feb 14, 2022	SELL	$4.94 - $7.69 $1.5 Million - $2.34 Million	-304,100 Reduced 83.16%	61,600 $376,000
Q3 2021 Nov 15, 2021	BUY	$5.3 - $7.89 $99,640 - $148,332	18,800 Added 5.42%	365,700 $1.94 Million
Q2 2021 Aug 11, 2021	BUY	$6.5 - $9.97 $1.71 Million - $2.63 Million	263,800 Added 317.45%	346,900 $2.55 Million
Q1 2021 May 17, 2021	BUY	$6.93 - $9.63 $575,883 - $800,253	83,100 New	83,100 $660,000

13.7M

21.9K

2.6K

Ticker SCYX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 32,651,800
Market Cap $33M
Description
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.